R Holland Cheng
Overview
Explore the profile of R Holland Cheng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
88
Citations
2192
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Olson N, Kolatkar P, Oliveira M, Cheng R, Greve J, McClelland A, et al.
Protein Eng
. 2024 Apr;
6(Suppl):1.
PMID: 38626270
No abstract available.
2.
Lambidis E, Chen C, Lumen D, Sanchez A, Sarparanta M, Cheng R, et al.
Eur J Pharm Sci
. 2022 Nov;
180:106336.
PMID: 36403717
Integrins are cell surface receptors involved in multiple functions vital for cellular proliferation. Various tumor cells overexpress αβ-integrins, making them ideal biomarkers for diagnostic imaging and tumor-targeted drug delivery. LXY30...
3.
Silverstein A, Dudaev A, Studneva M, Aitken J, Blokh S, Miller A, et al.
Prog Mol Biol Transl Sci
. 2022 Aug;
190(1):219-276.
PMID: 36008000
Medical abzymology has made a great contribution to the development of general autoimmunity theory: it has put the autoantibodies (Ab) as the key brick of the theory to the level...
4.
Cheng T, Chu H, Huang H, Li Z, Chen C, Shih Y, et al.
Int J Mol Sci
. 2022 Jul;
23(14).
PMID: 35886945
Nanotechnology is one of the scientific advances in technology. Nanoparticles (NPs) are small materials ranging from 1 to 100 nm. When the shape of the supplied nanoparticles changes, the physiological...
5.
Lambidis E, Chen C, Baikoghli M, Imlimthan S, Khng Y, Sarparanta M, et al.
Mol Pharm
. 2022 Jul;
19(8):2971-2979.
PMID: 35857429
Targeted delivery of diagnostics and therapeutics offers essential advantages over nontargeted systemic delivery. These include the reduction of toxicity, the ability to reach sites beyond biological barriers, and the delivery...
6.
Lambidis E, Lumen D, Koskipahta E, Imlimthan S, Lopez B, Sanchez A, et al.
Nucl Med Biol
. 2022 Jun;
114-115:151-161.
PMID: 35680503
Pretargeted PET imaging allows the use of radiotracers labeled with short-living PET radionuclides for tracing drugs with slow pharmacokinetics. Recently, especially methods based on bioorthogonal chemistry have been under intensive...
7.
Kheirolomoom A, Kare A, Ingham E, Paulmurugan R, Robinson E, Baikoghli M, et al.
Biomaterials
. 2022 Jan;
281:121339.
PMID: 35078042
Ex vivo programming of T cells can be efficacious but is complex and expensive; therefore, the development of methods to transfect T cells in situ is important. We developed and...
8.
Saha K, Sontheimer E, Brooks P, Dwinell M, Gersbach C, Liu D, et al.
Nature
. 2021 Apr;
592(7853):195-204.
PMID: 33828315
The move from reading to writing the human genome offers new opportunities to improve human health. The United States National Institutes of Health (NIH) Somatic Cell Genome Editing (SCGE) Consortium...
9.
Takada Y, Shimoda M, Maverakis E, Felding B, Cheng R, Takada Y
J Biol Chem
. 2021 Feb;
296:100399.
PMID: 33571526
CD40L is a member of the TNF superfamily that participates in immune cell activation. It binds to and signals through several integrins, including αvβ3 and α5β1, which bind to the...
10.
Chen C, Baikoghli M, Cheng R
Pharm Pat Anal
. 2021 Jan;
PMID: 33467938
The use of nanoparticulate systems to diagnose and treat tumors has gained momentum with the rapid development of nanomedicine. Many nanotheranostics fail due to insufficient bioavailability and low accumulation at...